The import of Theophylline and Aminophylline to Germany displays a declining trend over the forecast period from 2024 to 2028. Starting at 2.3204 million USD in 2024, the expected value diminishes by around 7.5% annually, reaching approximately 1.6425 million USD by 2028. This trend reflects a consistent decrease in Germany’s demand or possibly a shift to alternative treatments. While comparisons to 2023 data are constrained by the absence of it here, observed CAGR for these five years is negative.
Future trends to watch for include potential shifts in healthcare protocols or regulatory changes influencing demand. Monitoring emerging respiratory treatments could also impact these import numbers significantly.
